RxDoctor Payments Data

Rubeena Mian, MD

Psychiatry · Burr Ridge, ILNPI 1225171614

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $68,610 of the $87,641 with a category attached, or 78.3%. AbbVie accounts for 89.7% of it on its own, with 24 other manufacturers making up the rest. Among psychiatry clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$87,641in general payments, 2019–2025

Across 859 payments — averaging $102.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$79K
  • Takeda Pharmaceuticals U.S.A., Inc.$2K
  • Bausch Health US, LLC$1K
  • Lundbeck LLC$1K
  • Corium, LLC$882
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$615
  • plus $3K from 19 others

What the payments were for

  • Consulting fees$2,2503%
  • Speaking & faculty fees$68,61078%
  • Travel & lodging$1,5742%
  • Food & beverage$15,19617%
  • Education$110%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$87,641 in reported general payments places this provider in the 95th percentile of 1,344 psychiatry providers in Illinois.

See all psychiatry providers in Illinois

Medicare billing

Part B allowed, 2024
$35,482
Medicare patients
74
Services billed
340

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl25$37,831
Vilazodone Hcl34$5,241
Bupropion XlBupropion Hcl79$1,790
Quetiapine Fumarate61$1,312
Alprazolam134$1,073
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine34$970
Fluphenazine Hcl12$957
Venlafaxine Hcl ErVenlafaxine Hcl37$886
Aripiprazole19$838
Duloxetine Hcl73$833
Escitalopram Oxalate78$784
Fluoxetine Hcl45$779
Risperidone39$605
Sertraline Hcl53$556
Oxazepam11$531

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$78,631$37,83125 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,344 psychiatry providers in Illinois.

Other psychiatry in Burr Ridge

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →